Development of Novel Radiosensitizers through the National Cancer Institute's Small Business Innovation Research Program.

In conclusion, the NCI SBIR Development Center has funded the development of novel radiosensitizers leading to clinical trials of novel drugs in combination with radiation therapy. Continued follow-up is needed to determine if any of these novel radiosensitizers produce improved tumor control and/or overall survival. PMID: 32216707 [PubMed - as supplied by publisher]
Source: Radiation Research - Category: Physics Authors: Tags: Radiat Res Source Type: research